← SynDRA
RIDAFOROLIMUS
SynDRA canonical compound SYN0030042 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | MTOR |
|---|
| Mechanism of action | mTOR inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- MTOR inhibitor
- Serine/threonine-protein kinase mTOR inhibitor
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- deforolimus
- AP23573
- MK-8669
- jenzyl
- AP-23573
- MK8669
- Deforolimus
- AP23573, MK-8669, Ridaforolimus, Deforolimus
- MK 8669
- Taltorvic
- AP 23573
- 48Z35KB15K
- Ridaforolimus, >80%
- CHEBI:79700
- Ridaforolimus [USAN]
- RIDAFOROLIMUS [MI]
- RIDAFOROLIMUS [INN]
- RIDAFOROLIMUS [JAN]
- Deforolimus (MK-8669)
- Ridaforolimus [USAN:INN]
- Ridaforolimus (MK-8669)
- RIDAFOROLIMUS [MART.]
- UNII-48Z35KB15K
- RIDAFOROLIMUS [WHO-DD]
- GTPL7884
- SCHEMBL7719298
- CHEMBL2103839
- DTXSID001025942
- NSC757440
- Rapamycin, 42-(dimethylphosphinate)
- s1022
- ZINC169677038
- CCG-270602
- CS-0122
- DB06233
- NSC-757440
- NCGC00346481-02
- HY-50908
Look up RIDAFOROLIMUS in the interactive SynDRA portal →